These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 18160687)

  • 41. Myoblast transfer in the treatment of Duchenne's muscular dystrophy.
    Mendell JR; Kissel JT; Amato AA; King W; Signore L; Prior TW; Sahenk Z; Benson S; McAndrew PE; Rice R
    N Engl J Med; 1995 Sep; 333(13):832-8. PubMed ID: 7651473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.
    't Hoen PA; van der Wees CG; Aartsma-Rus A; Turk R; Goyenvalle A; Danos O; Garcia L; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Pharmacogenomics; 2006 Apr; 7(3):281-97. PubMed ID: 16610940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
    Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
    Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe.
    Takeshima Y; Nishio H; Sakamoto H; Nakamura H; Matsuo M
    J Clin Invest; 1995 Feb; 95(2):515-20. PubMed ID: 7860733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy.
    Mann CJ; Honeyman K; McClorey G; Fletcher S; Wilton SD
    J Gene Med; 2002; 4(6):644-54. PubMed ID: 12439856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.
    Tran VK; Takeshima Y; Zhang Z; Yagi M; Nishiyama A; Habara Y; Matsuo M
    J Med Genet; 2006 Dec; 43(12):924-30. PubMed ID: 16738009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.
    Bartlett RJ; Stockinger S; Denis MM; Bartlett WT; Inverardi L; Le TT; thi Man N; Morris GE; Bogan DJ; Metcalf-Bogan J; Kornegay JN
    Nat Biotechnol; 2000 Jun; 18(6):615-22. PubMed ID: 10835598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
    Arechavala-Gomeza V; Graham IR; Popplewell LJ; Adams AM; Aartsma-Rus A; Kinali M; Morgan JE; van Deutekom JC; Wilton SD; Dickson G; Muntoni F
    Hum Gene Ther; 2007 Sep; 18(9):798-810. PubMed ID: 17767400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
    Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
    Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.
    Pires VB; Simões R; Mamchaoui K; Carvalho C; Carmo-Fonseca M
    PLoS One; 2017; 12(7):e0181065. PubMed ID: 28742140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.
    De Angelis FG; Sthandier O; Berarducci B; Toso S; Galluzzi G; Ricci E; Cossu G; Bozzoni I
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9456-61. PubMed ID: 12077324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.
    Lu QL; Rabinowitz A; Chen YC; Yokota T; Yin H; Alter J; Jadoon A; Bou-Gharios G; Partridge T
    Proc Natl Acad Sci U S A; 2005 Jan; 102(1):198-203. PubMed ID: 15608067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rescue of dystrophin mRNA of Duchenne muscular dystrophy by inducing exon skipping.
    Matsuo M; Takeshima Y
    Acta Myol; 2005 Oct; 24(2):110-4. PubMed ID: 16550927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
    Hiller M; Falzarano MS; Garcia-Jimenez I; Sardone V; Verheul RC; Popplewell L; Anthony K; Ruiz-Del-Yerro E; Osman H; Goeman JJ; Mamchaoui K; Dickson G; Ferlini A; Muntoni F; Aartsma-Rus A; Arechavala-Gomeza V; Datson NA; Spitali P
    PLoS One; 2018; 13(10):e0204485. PubMed ID: 30278058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case of Becker muscular dystrophy resulting from the skipping of four contiguous exons (71-74) of the dystrophin gene during mRNA maturation.
    Patria SY; Alimsardjono H; Nishio H; Takeshima Y; Nakamura H; Matsuo M
    Proc Assoc Am Physicians; 1996 Jul; 108(4):308-14. PubMed ID: 8863344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphorothioate modification of chimeric 2´-O-methyl RNA/ethylene-bridged nucleic acid oligonucleotides increases dystrophin exon 45 skipping capability and reduces cytotoxicity.
    Malueka RG; Dwianingsih EK; Yagi M; Lee T; Nishida A; Iijima K; Takeshima Y; Matsuo M
    Kobe J Med Sci; 2015 Feb; 60(4):E86-94. PubMed ID: 25791417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging genetic therapies to treat Duchenne muscular dystrophy.
    Nelson SF; Crosbie RH; Miceli MC; Spencer MJ
    Curr Opin Neurol; 2009 Oct; 22(5):532-8. PubMed ID: 19745732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
    Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
    Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
    Wilton SD; Fletcher S
    Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.